takeda pharmaceutic-sp adr (TKPYY) Key Developments
Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited Updates Overall Survival Data from Two Adcetris Pivotal Phase 2 Clinical Trials
Dec 9 13
Seattle Genetics Inc. and Takeda Pharmaceutical Company Limited announced updated overall survival data from two ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinical trials in relapsed/refractory Hodgkin lymphoma (R/R HL) and relapsed/refractory systemic anaplastic large cell lymphoma (R/R sALCL) were presented at the 55(th) American Society of Hematology (ASH) Annual Meeting and Exposition taking place in New Orleans, LA, December 7-10, 2013. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30. Median overall survival (OS) of 40.5 months was reported in R/R HL, and was not yet reached in R/R sALCL. A pivotal, single-arm trial was conducted in 102 R/R HL patients after autologous stem cell transplant (ASCT) to assess the efficacy and safety of single-agent ADCETRIS. In addition, the trial was designed to determine duration of response, progression-free survival (PFS) and OS. Enrolled patients had received a median of more than three prior chemotherapy regimens. Patients received 1.8 milligrams per kilogram (mg/kg) of ADCETRIS administered through a 30-minute intravenous (IV) infusion every three weeks for up to 16 cycles for patients who achieved stable disease or better.
Takeda Pharmaceuticals Announces Management Changes
Dec 4 13
Takeda Pharmaceuticals has announced the creation of a new position of chief operating officer (COO) for French national Christophe Weber, who will take up the position in April 2014, and is also described in the firm's 30 November press release as a "candidate" for chief executive officer (CEO). Weber is currently the president of vaccines at GlaxoSmithKline, and CEO of GSK Biologicals SA in Belgium. Current Takeda president and CEO Yasuchika Hasegawa will be named chairman and CEO.
Takeda Pharmaceutical Company Limited Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2013; Provides Earnings Guidance for the Second Half Year 2014; Reiterates Earnings Guidance for the Fiscal Year 2014
Oct 31 13
Takeda Pharmaceutical Company Limited announced consolidated earnings results for the second quarter and six months ended September 30, 2013. For the quarter, the company reported net sales of JPY 418 billion compared to JPY 288.6 billion a year ago. Operating income was JPY 52.3 billion compared to JPY 46 billion a year ago. Ordinary income was JPY 44.3 billion compared to JPY 46.9 billion a year ago. Net income was JPY 35.6 billion or JPY 45 per share compared to JPY 32.2 billion or JPY 41 per share a year ago. EBITDA was JPY 102.6 billion compared to JPY 99 billion a year ago.
For the six months, the company reported net sales of JPY 828.3 billion compared to JPY 786.9 billion a year ago. Operating income was JPY 100 billion compared to JPY 108.6 billion a year ago. Ordinary income was JPY 96.7 billion compared to JPY 113.1 billion a year ago. Net income was JPY 64.7 billion or JPY 82 per share compared to JPY 119.8 billion or JPY 152 per share a year ago. EBITDA was JPY 213.4 billion compared to JPY 211.5 billion a year ago. Net debt was JPY 74 billion compared to JPY 133 billion a year ago. Net cash used in operating activities was JPY 7.1 billion compared to net cash provided by operating activities of JPY 180.4 billion a year ago. Payments for purchase of property, plant and equipment were JPY 44.4 billion compared to JPY 25.6 billion a year ago. Return on assets was 3.2% compared to 6.8% a year ago. Return on equity was 5.8% compared to 12.2% a year ago. Capital expenditure was JPY 34.3 billion compared to JPY 52.5 billion a year ago. Book value per share was JPY 2,889 compared to 2,422 a year ago.
The company provided earnings guidance for the Second half year and full year ending March 31, 2014. For the Second half year, the company forecasts, net income of JPY 30.3 billion or JPY 38 earnings per share on net sales of JPY 851.7 billion. The company forecasts ordinary income of 28.3 billion. For the second half, operating income is expected to be up JPY 40 billion. Expected EBITDA of 143.5 billion.
For the full year, the company reiterated, net income of JPY 95 billion or JPY 120 earnings per share on net sales of JPY 1,680 billion. The company forecasts operating income of JPY 140 billion and ordinary income of JPY 28.3 billion. The company expected EBITDA of JPY 355 billion.
Takeda Pharmaceutical Company Limited to Report First Half, 2014 Results on Oct 31, 2013
Oct 20 13
Takeda Pharmaceutical Company Limited announced that they will report first half, 2014 results on Oct 31, 2013
Takeda Pharmaceutical Company Limited Presents at 19th Annual BIO-Europe International Partnering Conference, Nov-04-2013 through Nov-06-2013
Oct 16 13
Takeda Pharmaceutical Company Limited Presents at 19th Annual BIO-Europe International Partnering Conference, Nov-04-2013 through Nov-06-2013. Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria. Presentation Date & Speakers: Nov-04-2013, Terence G. Porter, VP, Search and Evaluation, Global Business Development.